Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

February 7, 2014

Primary Completion Date

June 30, 2020

Study Completion Date

October 31, 2020

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d

Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.

DRUG

docetaxel 75 mg/m2 + prednisone 10 mg/d

Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.

Trial Locations (17)

12002

Consorcio Hospitalario Provincial de Castellón, Castellon

14004

Complejo Hospitalario Regional Reina Sofía, Córdoba

19002

Hospital Universitario de Guadalajara, Guadalajara

28007

Hospital General Universitario Gregorio Marañón, Madrid

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Hospital Virgen de La Victoria, Málaga

33006

Hospital Universitario Central de Asturias, Oviedo

36036

Complexo Hospitalario Universitario de Vigo, Vigo

41013

Complejo Hospitalario Regional Virgen Del Rocio, Seville

46009

Fundación Instituto Valenciano de Oncología, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

07120

Hospital Universitari Son Espases, Palma de Mallorca

08916

Hospital Universitari Germans Trias I Pujol, Badalona

08025

Hospital de La Santa Creu I Sant Pau, Barcelona

08036

Hospital Clinic I Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT02036060 - Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. | Biotech Hunter | Biotech Hunter